An in-silico approach on essential oil molecules as apoptosis inducer in cancer chemotherapy
Loading...
Files
Date
2017
Journal Title
Journal ISSN
Volume Title
Publisher
Innovations in Pharmaceuticals and Pharmacotherapy
Abstract
Essential oils (EOs) are very engrossing natural plant products and apart from this they possess various biological properties. It has been reported that these essential oil molecules are able to inhibit tumor cell proliferation and induce tumor cell death by inhibiting multiple cancer-specific targets including the suppression of anti-apoptotic pathways i.e., BCL-2, BCL-XL, MCL-1, and NFκb. This study was conducted with the objective of exploring the anticancer activity of herbs and spices, with special reference to its potential to inhibit anti-apoptotic pathways by studying their interaction pattern with the selective inhibitors of the particular receptors. Hence a comparative in-silico study was done in which the essential oil molecules were docked with specific anti-apoptotic receptors with respect to the particular known
inhibitor of that receptor therefore the binding affinity of the essential oil molecule with that of the receptor site was analyzed. It has been observed that the phytochemicals like capsaicin have an impressive binding affinity for NFκb
receptor, BCL-2 as compared to its standard inhibitors, which shows that the phytochemical has stronger binding affinity for receptor. These docking results hereby apparently tells us that the binding affinity of the essential oil molecules are either comparable or more than that of the specific inhibitors of the receptors hence in future drug molecules can be synthesized keeping in view the strong binding affinity of these molecules with the receptors.
Description
Keywords
Essential oils, Anti-apoptosis, In-silico, Phytochemicals, Anticancer Activity
Citation
Bhalla, Y., Singla, R., Jaitak, V., Sapra, S., Innovations in Pharmaceuticals and Pharmacotherapy (2017) An in-silico approach on essential oil molecules as apoptosis inducer in cancer chemotherapy. Innovations in Pharmaceuticals and Pharmacotherapy4 (1), 10-21.